George, that is what I thought too. In fact, when RVX said they were applying for BT designation, I assumed all along that they would be doing it for CKD.  So this BT for CVD is a head scratcher for me.  I mean BT was supposed to be given for Phase 2 drugs, not completed Phase 3...although I suppose the FDA can decide whatever they want.

I sure hope a BT is on the way for CKD.  Can someone enlighten us on whether that is on the cards?

If it does, then Seeking Alpha's article suggests that RVX is going to be the best performing stock in Canada this year.